MedDataX Logo

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

NCT ID: NCT02846896

Last Updated: 2025-08-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

501 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking. Epidemiology can be a powerful tool in yielding important clues as to burden and etiology of diseases. In addition, the investigators study will be the first one carried out in the country on PBC, and therefore will raise disease awareness and create a network.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

NCT02932449

Biliary Cirrhosis, Primary
COMPLETED

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

NCT03420768

Hepatic Cirrhosis Liver Fibrosis
COMPLETED PHASE2

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05292872

Primary Biliary Cholangitis
COMPLETED

Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial (AMBIC)

NCT03878563

Liver Cirrhoses
TERMINATED

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

NCT02078882

Primary Biliary Cirrhosis
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Biliary Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PBC patients living in Switzerland

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vifor Pharma

INDUSTRY

Sponsor Role collaborator

Intercept Pharmaceuticals

INDUSTRY

Sponsor Role collaborator

Fondazione Epatocentro Ticino

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondazione Epatocentro Ticino

Lugano, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Terziroli Beretta-Piccoli B, Stirnimann G, Cerny A, Semela D, Hessler R, Helbling B, Stickel F, Kalid-de Bakker C, Bihl F, Giostra E, Filipowicz Sinnreich M, Oneta C, Baserga A, Invernizzi P, Carbone M, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clin Rev Allergy Immunol. 2018 Apr;54(2):295-306. doi: 10.1007/s12016-017-8656-x.

Reference Type DERIVED
PMID: 29181702 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SwissPBC - SASL36

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
NCT02308111 TERMINATED PHASE4
A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
NCT05293938 WITHDRAWN
Primary Sclerosing Cholangitis in Children
NCT04181138 RECRUITING
Monitoring the Response of Combination Ursodiol and Seladelpar Treatment
NCT07122206 NOT_YET_RECRUITING
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
NCT04620733 COMPLETED PHASE3
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
NCT00550862 TERMINATED PHASE2
Pentoxifylline for Primary Biliary Cirrhosis
NCT01249092 COMPLETED PHASE2
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
NCT04526665 ACTIVE_NOT_RECRUITING PHASE3
Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
NCT06865924 ACTIVE_NOT_RECRUITING NA
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
NCT04950764 COMPLETED PHASE1
A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain
NCT07191704 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
NCT01899703 COMPLETED PHASE2
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
NCT02609048 TERMINATED PHASE2
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
NCT02135536 COMPLETED PHASE2
Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis
NCT00393185 WITHDRAWN PHASE1
Pilot Study of FFP104 Dose Escalation in PBC Subjects
NCT02193360 UNKNOWN PHASE1/PHASE2
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842 RECRUITING PHASE3
Study in Patients With Decompensated Liver Cirrhosis
NCT06380335 ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136 RECRUITING PHASE2
B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis
NCT02376335 COMPLETED PHASE2
Moexipril for Primary Biliary Cirrhosis
NCT00588302 COMPLETED PHASE2
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis
NCT01614405 TERMINATED NA
IBAT Inhibitor A4250 for Cholestatic Pruritus
NCT02360852 TERMINATED PHASE2
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
NCT00006168 COMPLETED PHASE3
Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis
NCT00406237 COMPLETED PHASE1